AU2020212019B2 - Methods of treating addiction - Google Patents

Methods of treating addiction Download PDF

Info

Publication number
AU2020212019B2
AU2020212019B2 AU2020212019A AU2020212019A AU2020212019B2 AU 2020212019 B2 AU2020212019 B2 AU 2020212019B2 AU 2020212019 A AU2020212019 A AU 2020212019A AU 2020212019 A AU2020212019 A AU 2020212019A AU 2020212019 B2 AU2020212019 B2 AU 2020212019B2
Authority
AU
Australia
Prior art keywords
compound
formula
drug
present disclosure
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020212019A
Other languages
English (en)
Other versions
AU2020212019A1 (en
Inventor
Robert Davis
Peng Li
Sharon Mates
Gretchen Snyder
Kimberly Vanover
Wei Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of AU2020212019A1 publication Critical patent/AU2020212019A1/en
Application granted granted Critical
Publication of AU2020212019B2 publication Critical patent/AU2020212019B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020212019A 2019-01-23 2020-01-23 Methods of treating addiction Active AU2020212019B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795899P 2019-01-23 2019-01-23
US62/795,899 2019-01-23
PCT/US2020/014818 WO2020154519A2 (en) 2019-01-23 2020-01-23 Methods of treating addiction

Publications (2)

Publication Number Publication Date
AU2020212019A1 AU2020212019A1 (en) 2021-09-16
AU2020212019B2 true AU2020212019B2 (en) 2025-04-17

Family

ID=71735540

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020212019A Active AU2020212019B2 (en) 2019-01-23 2020-01-23 Methods of treating addiction

Country Status (10)

Country Link
US (1) US20220088014A1 (https=)
EP (1) EP3914235A4 (https=)
JP (1) JP7555343B2 (https=)
KR (1) KR102928755B1 (https=)
CN (2) CN118105390A (https=)
AU (1) AU2020212019B2 (https=)
CA (1) CA3125777A1 (https=)
IL (1) IL284797A (https=)
MX (2) MX2021008717A (https=)
WO (1) WO2020154519A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
JP7520013B2 (ja) 2018-12-17 2024-07-22 イントラ－セルラー・セラピーズ・インコーポレイテッド 置換複素環縮合γ－カルボリンの合成
IL315005B2 (en) 2018-12-17 2026-04-01 Intra Cellular Therapies Inc Synthesis of condensed gamma-carbolines and converted heterocycles
JP7649743B2 (ja) 2018-12-21 2025-03-21 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
MX2024004725A (es) * 2021-10-19 2024-05-10 Intra Cellular Therapies Inc Metodos novedosos.
CN116210637A (zh) * 2021-12-06 2023-06-06 中国科学院深圳先进技术研究院 一种成瘾药物戒断后复吸相关调控基因及其筛选方法
WO2024145659A1 (en) * 2022-12-30 2024-07-04 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor
WO2025257090A1 (en) 2024-06-10 2025-12-18 Interquim, S.A. Process for the preparation of synthesis intermediates of lumateperone and lumateperone analogues
CN119912455B (zh) * 2025-01-22 2025-09-23 成都臻拓医药科技有限公司 一种卢美哌隆中间体化合物的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170319580A1 (en) * 2016-01-26 2017-11-09 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) * 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126143A1 (en) * 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2019023062A1 (en) * 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
WO2020132605A1 (en) * 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE277048T1 (de) * 1999-06-15 2004-10-15 Bristol Myers Squibb Pharma Co Substituierte hetercyclisch kondensierte gamma carboline
EP3658144B1 (en) * 2017-07-26 2022-01-26 Intra-Cellular Therapies, Inc. Pyridopyrroloquinoxaline compounds, their compositions and uses in therapy
EP3801527B1 (en) * 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170319580A1 (en) * 2016-01-26 2017-11-09 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) * 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126143A1 (en) * 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2019023062A1 (en) * 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
WO2020132605A1 (en) * 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compounds

Also Published As

Publication number Publication date
CN113329742A (zh) 2021-08-31
EP3914235A2 (en) 2021-12-01
CA3125777A1 (en) 2020-07-30
WO2020154519A3 (en) 2020-09-17
EP3914235A4 (en) 2022-09-07
CN118105390A (zh) 2024-05-31
JP7555343B2 (ja) 2024-09-24
WO2020154519A2 (en) 2020-07-30
KR102928755B1 (ko) 2026-02-19
US20220088014A1 (en) 2022-03-24
KR20210118889A (ko) 2021-10-01
JP2022518495A (ja) 2022-03-15
MX2021008717A (es) 2021-10-26
MX2025009723A (es) 2025-09-02
AU2020212019A1 (en) 2021-09-16
IL284797A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
US12173004B2 (en) Pharmaceutical compositions comprising heterocycle fused gamma carboline prodrugs
AU2020212019B2 (en) Methods of treating addiction
US20220296591A1 (en) Organic compounds
US12331052B2 (en) Organic compounds
AU2020254812B2 (en) Methods of treating neuropathic pain
HK40059557A (en) Methods of treating addiction
HK40030440A (en) Pyridopyrroloquinoxaline compounds, their compositions and uses in therapy
HK40030440B (en) Pyridopyrroloquinoxaline compounds, their compositions and uses in therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)